This study is accepting new patients by invitation only

Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101

a study on HIV/AIDS

Summary

Eligibility
for males ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Priscilla Hsue
Headshot of Priscilla Hsue
Priscilla Hsue

Description

Summary

Participants who receive EBT-101 in a parent protocol will be eligible to participate in this long-term follow-up (LTFU) study (EBT-101-002).

Official Title

Long-Term Follow-Up Study of HIV-1 Infected Adults Exiting a Parent Study Where EBT-101 Was Administered

Details

Participants who receive EBT-101 in a parent protocol will be eligible to participate in this LTFU study (EBT-101-002). All participants will have follow-up visits every six months until Year 5 post EBT-101. Thereafter, all participants will have follow-up visits annually on the anniversary of EBT-101 administration until study completion at Year 15.

Keywords

HIV-1-infection, CRISPR, Gene Therapy, adeno-associated virus serotype 9 (AAV9), EBT-101

Eligibility

You can join if…

Open to males ages 18 years and up

  • Willing and able to provide written, signed informed consent
  • Participants who received the investigational study intervention EBT-101 in a parent study

You CAN'T join if...

• Participants who did not receive EBT-101 in a parent study

Locations

  • Quest Clinical Research
    San Francisco California 94115 United States
  • Washington University
    Saint Louis Missouri 63110 United States
  • Cooper Health
    Camden New Jersey 08103 United States

Lead Scientist at UCSF

  • Priscilla Hsue
    Dr. Hsue trained in Internal Medicine in the Molecular Medicine Training Program at UC San Francisco and in Cardiovascular Medicine at UC San Francisco. She served as Chief Cardiology Fellow during this time. She has been on the faculty in the Department of Medicine at San Francisco General Hospital since 2002.

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Excision BioTherapeutics
ID
NCT05143307
Phase
Phase 1 HIV/AIDS Research Study
Study Type
Interventional
Participants
Expecting 9 study participants
Last Updated